Eli Lilly | LLY - Ordinary Share Capital



Eli Lilly reported $946.83M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Abbott USD 25.12B 28M Mar/2025
ALKERMES USD 165.05M 163.25M Jun/2025
Amgen USD 538M 33.04B Jun/2025
AstraZeneca USD 1.55B 1.16B Jun/2025
Baxter International USD 683M 0 Dec/2024
Biogen USD 146.6M 146.5M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Drreddys Laboratories INR 832.37M 1.63M Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
GlaxoSmithKline GBP 4.15B 2.8B Jun/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
J&J USD 3.12B 0 Mar/2025
Medtronic USD 128K 128K Apr/2025
Merck USD 1.79B 0 Mar/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Novartis USD 793M 0 Dec/2024
Novartis USD 1.94B 1.14B Jun/2025
Novo Nordisk 4.44B 3.99B Jun/2025
Perrigo USD 137.6M 6.56B Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Prestige Brands USD 49.21M 48.65M Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Roche Holding CHF 107M 0 Jun/2024
Sanofi 1.22B 36.5M Jun/2025
Sanofi 1.22B 36.5M Jun/2025
United Therapeutics USD 45.22M 44.42M Jun/2025
Zoetis USD 443.95M 438.95M Jun/2025